Bihua Chen - 01 Jul 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BBOT
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 16:34:53 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Bihua Chen

Key filing fact

Bihua Chen filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 06 Jul 2026.

Key facts

This page summarizes Bihua Chen's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Jul 2026, 16:34.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001599214 Primary reporting owner

Chen Bihua

Relationship: Director, 10%+ Owner
Address: C/O HELIX ACQUISITION CORP. II, 200 CLARENDON STREET, 52ND FLOOR, BOSTON
Signature: /s/ Bihua Chen
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBOT transaction

Common Stock

Other

Transaction value
Shares: -4,528,186
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jul 2026
Ownership: Via Helix Holdings II LLC
Footnotes: F1, F5

BBOT transaction

Common Stock

Other

Transaction value
Shares: +2,692,459
Change %: +123%
Price: $0.000000^*
Shares after: 4,879,995
Date: 01 Jul 2026
Ownership: Via Fund III
Footnotes: F2, F6

BBOT transaction

Common Stock

Other

Transaction value
Shares: +1,704,862
Change %: +52%
Price: $0.000000^*
Shares after: 5,010,332
Date: 01 Jul 2026
Ownership: Via Fund V
Footnotes: F3, F6

BBOT transaction

Common Stock

Other

Transaction value
Shares: +130,865
Change %: +2.2%
Price: $0.000000^*
Shares after: 6,083,221
Date: 01 Jul 2026
Ownership: Via Master Fund
Footnotes: F4, F6

BBOT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,905,046
Date: 01 Jul 2026
Ownership: Via Fund IV
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents a pro rata distribution to the members of Helix Holdings II LLC (the "Sponsor") for no consideration.

Footnote F2

Cormorant Private Healthcare Fund III, LP ("Fund III"), which is an investment vehicle managed by Cormorant Asset Management, LP ("CAM"), is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.

Footnote F3

Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.

Footnote F4

Cormorant Global Healthcare Master Fund, LP ("Master Fund"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.

Footnote F5

Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly.

Footnote F6

CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC remarks

Ms. Chen serves on the Board of Directors of the Issuer. Sponsor and the Cormorant Funds may be deemed to be directors by deputization as a result of the service of Ms. Chen.